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Abstract
Canine Diffuse Large B-cell Lymphoma (cDLBCL) is an aggressive cancer with variable clinical response. Despite recent
attempts by gene expression profiling to identify the dog as a potential animal model for human DLBCL, this tumor remains
biologically heterogeneous with no prognostic biomarkers to predict prognosis. The aim of this work was to identify copy
number aberrations (CNAs) by high-resolution array comparative genomic hybridization (aCGH) in 12 dogs with newly
diagnosed DLBCL. In a subset of these dogs, the genetic profiles at the end of therapy and at relapse were also assessed. In
primary DLBCLs, 90 different genomic imbalances were counted, consisting of 46 gains and 44 losses. Two gains in chr13
were significantly correlated with clinical stage. In addition, specific regions of gains and losses were significantly associated
to duration of remission. In primary DLBCLs, individual variability was found, however 14 recurrent CNAs (.30%) were
identified. Losses involving IGK, IGL and IGH were always found, and gains along the length of chr13 and chr31 were often
observed (.41%). In these segments, MYC, LDHB, HSF1, KIT and PDGFRa are annotated. At the end of therapy, dogs in
remission showed four new CNAs, whereas three new CNAs were observed in dogs at relapse compared with the previous
profiles. One ex novo CNA, involving TCR, was present in dogs in remission after therapy, possibly induced by the
autologous vaccine. Overall, aCGH identified small CNAs associated with outcome, which, along with future expression
studies, may reveal target genes relevant to cDLBCL.
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Introduction
Diffuse Large B-cell Lymphoma (DLBCL) is the most common
canine lymphoproliferative tumor, accounting for approximately
50% of non-Hodgkin’s lymphomas occurring in this species. In
dogs, DLBCL exhibits a different clinical behavior based on the
variable responses to the same treatments, even within the same
clinical stage [1]. Recently, gene expression profiling in canine
DLBCL has shown two biologically distinct subtypes. The
constitutive activation of the nuclear factor kB pathway has also
been identified as a distinctive feature, but other possible
mechanisms may underlie the pathogenesis of this tumor [2,3].
Furthermore, dogs with DLBCL have been studied in a
therapeutic clinical trial using an autologous vaccine, possibly
being relevant to translational therapy [4].
In human patients, molecular heterogeneity within lymphoma
histotypes has been ascribed to an array of chromosomal
abnormalities, such as chromosomal translocations and deletions
of tumor suppressor genes [5]. To date, cytogenetic aberrations in
DLBCL have been scarcely investigated in dogs. In 2011, Thomas
and colleagues [6] made substantial progresses by analyzing a high
number of canine lymphomas with a Bacterial Artificial Chro-
mosome (BAC) based microarray platform for comparative
genomic hybridization (CGH). However, more recently, micro-
array-based formats, using large insert genomic clones, cDNAs or
oligonucleotides, have replaced metaphase chromosomes provid-
ing advantages, such as a higher resolution, and the ability to
directly map the copy number changes to the genome sequence.
Through high-resolution genome-wide DNA microarray analyses,
many novel tumor-specific microdeletions and amplifications have
been discovered in different human tumors [7–11]. In human
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lymphoma, the improved resolution of array CGH (aCGH)
formats has increased the number of the identified genomic
aberrations and, importantly, a number of copy number
alterations (CNAs) detected by aCGH, that were undetectable
by metaphase CGH, have been associated with prognosis and
predicted outcome [12]. A similar approach has not been
considered for canine lymphomas yet.
The first aim of this work was to identify genomic regions or
even gene-specific CNAs in canine DLBCL at the currently
highest available resolution. To this end, we applied oligonucle-
otide aCGH (oligo aCGH) to pair primary DLBCLs and relative
skin punch biopsies. An association between regions of DNA
CNAs and response to therapy was also investigated.
Numerous observations have demonstrated that at different
time points during chemotherapy new alterations affecting specific
chromosomal regions become evident. In human lymphoma, these
alterations represent the outgrowth of more malignant subclones
associated with a more aggressive phenotype [13]. In veterinary
medicine, so far, no data have documented molecular genetic
alterations acquired at relapse. To address also this point, in a
reduced number of dogs, we compared genomic imbalances
between DLBCLs matched samples at initial presentation and at
relapse.
Materials and Methods
Dogs and samples
The study cohort consisted of 12 dogs with newly-diagnosed
multicentric DLBCL that underwent complete staging work-up,
and that were treated with chemotherapy or chemo-immunother-
apy. The diagnosis of DLBCL was obtained by histopathological
and immunohistochemical analysis (CD20 and CD79) of one
enlarged lymph node, that was surgically removed at initial
presentation. A portion of the tumor was preserved frozen in
RNAlater solution (Life Technologies, Carlsbad, CA) under sterile
conditions. Medical records of all dogs were reviewed to obtain
relevant clinical information, including breed, sex, age, clinical
stage, substage and treatment. Time to progression (TTP) was
measured as the interval between initiation of treatment and
progressive disease (PD). Dogs not experiencing PD at the end of
the study and dogs lost to follow-up before PD were censored for
TTP analysis. Lymphoma-specific survival (LSS) was measured as
the interval between initiation of treatment and lymphoma-related
death. Censoring was done for dogs that were lost to follow-up, for
dogs that died from lymphoma-unrelated causes, and for dogs that
were still alive at the end of the study. After having completed the
treatment protocol and at relapse, dogs underwent complete end-
staging or re-staging, respectively, including PCR for antigen
receptor rearrangement on peripheral blood, bone marrow and
lymph node tissue. At diagnosis, a skin punch biopsy was also
obtained from all dogs.
The study was approved by the Ministry of Education,
Universities and Research, University Committee, Rome, Italy
(protocol 20086MSFH3), and a mandatory written consent from
owners was obtained.
DNA extraction
Genomic DNA was extracted from lymph nodes and skin
punches using the DNeasy Blood & Tissue Kit (QIAGEN,
Valencia, CA, USA) according to the manufacturer’s instructions.
DNA concentration and quality were measured by a Nanodrop
ND-1000 spectrophotometer (Nanodrop Technologies, Wilming-
ton, DE), Qubit fluorometer (Life Technologies) and by denatur-
ing gel electrophoresis.
Array Comparative Genomic Hybridization
In total, the DNA obtained from 19 lymph node specimens,
together with the paired skin biopsies were analyzed using a
180,000-feature SurePrint G3 Canine CGH Microarray
(46180 K, Agilent Technologies), comprising repeat-masked 60-
mer oligonucleotides distributed at approximately 2.7 kb intervals
throughout the dog genome assembly. Tumor and reference DNA
samples were labelled independently with cyanine 3-deoxyuridine
triphosphate (dUTP) and cyanine 5-dUTP, respectively, using
SureTag Complete DNA Labeling Kit. Oligo aCGH analysis was
performed following the manufacturer’s recommendations, using
an Oligo aCGH/ChIP-on-chip Hybridization Kit (Agilent Tech-
nologies), Canine Cot-1 DNA (Applied Genetics Laboratories,
Inc., FL, USA) and Oligo aCGH/ChIP-on-chip Wash Buffer 1
and Oligo aCGH/ChIP-on-chip Wash Buffer 2 (Agilent Tech-
nologies). Arrays were scanned at 3 mm resolution using an Agilent
G2565CA scanner, and image data were processed using Feature
Extraction version 10.7, Genomic Workbench version 6.0 and a
CGH11050oct2012 protocol (Agilent Technologies). Data were
filtered to exclude probes exhibiting non uniform hybridization or
signal saturation and were normalized using the centralization
algorithm with a threshold of eight. The ADM-1 algorithm was
applied to define CNAs using a ‘three probes minimum’ filter and
a threshold of eight without a fuzzy zero correction. To minimize
the risk of generating data representing naturally occurring copy
number variants not associated with the tumor, reference DNA
samples used in this study were derived from the dog’s own skin
biopsy. Thus, each lymphoma specimen was associated with the
related skin biopsy.
Data Analysis
The Cy5/Cy3 intensity ratios for each spot were converted into
log2 ratios. Aberrant chromosome intervals (except for X
chromosome) were selected by using Agilent Genomic Workbench
v. 7.0. Copy number gain was defined as a log 2 ratio .0.25 and a
copy number loss was defined as a log 2 ratio ,20.25. High-level
gain or amplification were defined as a log 2 ratio .1 and 1.5
respectively.
Chromosomal locations were defined in terms of their
Megabase (Mb) position. For comparison of genomic imbalances
shared between human and dog, orthologous regions on human
chromosomes were identified using the Ensemble Genome
Browser (http://www.ensembl.org/index.html).
In order to find biological ontologies and pathways enriched in
recurrent CNAs, functional annotations of all genes mapping to
those aberrant regions was performed using the Functional
Annotation Tool Database for Annotation, Visualization, and
Integrated Discovery (DAVID) Bioinformatics Resources 6.7,
NIAID/NIH (http://david.abcc.ncifcrf.gov/summary.jsp), server
‘‘Biological process’’ (BP), ‘‘Molecular function’’ (MF) and
‘‘Cellular component’’ (CC) annotations were performed by
setting gene count = 3 and ease = 0.05. The same parameters
were employed also for ‘‘Kyoto encyclopedia gene and genome’’
(KEGG) pathway analysis.
Statistical analysis
For statistical analysis, dogs were divided into two groups based
on response to treatment. Dogs that failed to achieve a complete
response to treatment or that achieved an initial response but
relapsed before treatment completion were defined as ‘‘therapy-
resistant’’ (n 6), whereas dogs that maintained a complete response
after the end of treatment were defined as ‘‘therapy-responsive’’ (n
6). Associations between specific CNAs and the two groups were
tested using Fisher exact test. Analyses were performed using SPSS
Genetic Heterogeneity of Diffuse Large B-Cell Lymphoma in Dog
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software (version 21, SPSS, Chicago, IL, USA). To identify genes
with frequent abnormalities in multiple samples, minimal common
regions (MCRs) were identified. MCRs represented the maximal
overlapping zone across samples within an abnormal (gained/lost)
chromosomal region [14], and were defined by means of Agilent
Genomic Workbench v. 7.0 by applying T-Test Common
Aberration algorithm with Overlap threshold of 0.8 and p-value
,0.05. In the present study, aberrations shared in at least four
cases ($30% of cases) were considered as recurrent MCRs.
Genomic Identification of Significant Targets in Cancer
(GISTIC) algorithm as implemented in CGHtools software was
then used to identify CNAs significantly associated with clinical
outcome. The GISTIC module identifies regions of the genome
that are significantly amplified or deleted across a set of samples.
Each aberration is assigned a G-score that considers the amplitude
as well as the frequency of its occurrence across samples. False
Discovery Rate q-values are then calculated for the aberrant
regions, and regions with q-values below a user-defined threshold
are considered significant. Log2ratios $0.25 and #–0.25 were
assigned as threshold for gain and loss detection while a False
Discovery Rate (FDR) #0.05 was set as limit of significance.
Results
Clinical results
Twelve dogs with newly-diagnosed, previously untreated,
multicentric centroblastic DLBCL were prospectively enrolled.
Of these, 7 were from a series that was included in a previous
clinical trial [4]. Five dogs that received the same chemo-
immunotherapeutic treatment, but that were not included in the
published trial, were also enrolled. Overall, 9 dogs received the
same chemo-immunotherapy protocol, and 3 were treated by
means of chemotherapy only. Chemotherapy did not differ among
dogs. The main clinical characteristics of these dogs are listed in
Table S1 in File S1.
Genomic pattern of aberrations in DLBCL
In pre-treatment DLBCLs, oligo aCGH detected both small
and whole-chromosome areas of gains as well as deletions. The
pattern of genomic aberrations consisted of 90 different genomic
imbalances (mean per tumor, 17; range, 2–29), and included 46
genomic gains (mean per tumor, 9; range, 4–22), and 44 losses
(mean per tumor, 7; range 2–18) (Figure 1). The DLBCL in one
dog showing the highest number of aberrations relapsed in a short
time (31 days) (Table S2 in File S1).
In the analysis of the three matched relapse samples, a lower
number of chromosomal changes was detected compared with
primary DLBCLs: 15 different genomic imbalances (mean per
tumor, 10; range, 7–14), distributed as 8 gains (mean per tumor, 6;
range 5–8) and 7 losses (mean per tumor, 4; range 2–6). In all
cases, at least one common genomic abnormality was found both
in the primary DLBCL and at relapse, confirming the clonal
relationship between matched tumors. The most frequent loss at
relapse was in Canis Familiaris (CFA) 17q15 (37.6 to 37.8 Mb),
whereas the most frequent gain was along the length of the whole
chr13. In one dog, between the time of diagnosis and relapse, the
acquisition of 3 new genomic alterations was also observed. All
were identified as losses (CFA 8q11, 2.4 to 2.9 Mb; CFA 8q33.2,
nearly 70.7 Mb; CFA 16q11, nearly 1.9 Mb). One dog displayed
the same profile in the pre-treatment DLBCL and at relapse
(Table S3 in File S1).
At the end of treatment, four dogs in clinical remission
underwent end-staging lymphadenectomy. In all cases, the
histological diagnosis was compatible with follicular hyperplasia,
and clonality was negative. Analysis of aCGH data detected 10
different genomic imbalances in total (mean per sample, 4; range
4–4), distributed as 1 gain (mean per sample 1) and 9 losses (mean
per sample, 3: range 3–4). A total of five new losses were observed
in the dogs that were in remission at the end of treatment (CFA
9q11, nearly 1.0 Mb; CFA 16q12, 6.7 to 6.9 Mb; CFA 19q21,
20.2 to 20.3 Mb; CFA 37q14, nearly 18.9 Mb). The genomic loss
in CFA 8q11 (2.4 to 2.9 Mb) was the most frequently found (75%).
One new gain (CFA 25q24, 51.1 to 51.2 Mb) was found in one
dog (Table S3 in File S1).
One example of a single genomic aberration at different time
point is shown in Figure 2.
Minimum common regions (MCRs) analysis
To identify genes with frequent abnormalities in multiple
samples, MCRs were identified in pre-treatment DLBCLs. In
Table 1, MCRs and the known genes that reside within these
DNA segments are shown. Nine MCRs were gained in $41% of
cases; the three most common regions were located in chr13 (CFA
13q13, 24.3 to 26.2 Mb; CFA 13q13-q21.2, 26.2 to 34.4 Mb;
CFA 13q21.1, 37.4 to 38.2 Mb), and were present in $66% of
cases. The other 4 gains located in the same chromosome (0.03 to
16.6 Mb; CFA 13q12-q13, 16.6 to 24.4 Mb; CFA 13q21.1, 34.4
to 37.4 Mb; CFA 13q21.1-22.2, 38.2 to 63.0 Mb) had a frequency
that ranged between 50% and 58%. Conversely, gain in the whole
chr31 was less frequently found (41%). Five MCRs were lost in $
50% of samples. The three most frequently lost MCRs were
located in CFA 8q33.3 (72.9 to 74.1 Mb), CFA 17q15 (37.6 to
37.8 Mb) and CFA 26q22 (25.4 to 27.6 Mb), and observed in $
91% of cases. Immunoglobulin heavy chain (IGH), immunoglob-
ulin kappa (IGK) and lambda (IGL) genes are encoded in these
segments.
Genomic pattern of aberration correlated with clinical
outcomes
Clustering techniques are commonly used to identify molecular
features correlated with clinical outcomes. In the present study,
both probes log2ratio and discrete values assigned to genome
region were employed to perform unsupervised hierarchical
clustering of primary DLBCLs, but both approaches failed to
provide consistent results, probably due to the limited number of
samples in this study (data not shown).
Microarray data were then interrogated using the GISTIC
analysis to identify CNAs whose frequency was significantly
increased in the therapy-resistant or the therapy-responsive group.
A total of 7 discrete regions whose distribution showed significant
variation between the two groups were identified. In particular,
the extensive gain of chr13 was significantly more frequent in
therapy-responsive DLBCLs (5/6) compared to therapy-resistant
DLBCLs (2/6). Conversely, the gain of the entire chr31 was more
frequently found in the therapy-resistant group. The extensive
gain of chr13 was significantly correlated with stage III and IV
(Fisher exact test, p = 0.02). Interestingly, the gain in the chr31 was
associated with a shorter duration of remission (117 days vs 300
days, p = 0.009).
Other 4 gains were found to be specific of therapy-resistant
DLBCLs: CFA 3q34 (74.56 to 74.61 Mb), CFA 26q13 (12.68 to
12.69 Mb), CFA 23q11 (0.92 to 0.95 Mb) which includes TCEA3,
and CFA 33q14 (17.27 to 17.29 Mb) that comprises CD200R1, a
receptor restricted to the surface of myeloid lineage cells.
Noteworthy, the segmentation algorithm employed by GISTIC
showed a sub-regional variation along the CNA identified in chr8
(loss of Mb 72.95 to 74.12) by ADM-1 algorithm. By applying
GISTIC approach, the 65% of this region, containing the canine
Genetic Heterogeneity of Diffuse Large B-Cell Lymphoma in Dog
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IGH variable (IGHV) locus, was lost in both groups of dogs, while
the incidence of the loss of the first 0.4 Mb, that holds four
members of IGH constant gamma (IGHG1, IGHG2, IGHG3 and
IGHG4), was significantly elevated in the therapy-resistant dogs.
Comparative analysis of genomic imbalance in canine
and human DLBCL
Orthologous chromosomal regions in canine and human
genome were examined to assess evolutionary conserved CNAs
between cDLBCL and human DLBCL (hDLBCL) (Table 2). To
achieve this comparison, data of several studies describing frequent
chromosome imbalances in activated B-cell-like (ABC) and
germinal center B-cell-like (GCB) DLBCLs were employed
[5,15–19].
Comparative analysis of CNAs highlighted several regions
shared between the two species. Within the gains, Homo Sapiens
(HSA) 1p36.11, 7p13, 8q21-q26, 16p11-p13, 18q21.1 have been
described to be frequently associated with pathogenesis of
hDLBCL, and in particular HSA 8q24 and 19q13 are known to
be responsible for amplification of MYC and TGFB1, respectively.
Similar imbalances were found in the dog, and related to the
extensive gain of canine chr13. Of interest are loss of HSA 4p12
and 4q12 in hDLBCL [18], which comprise KIT and PDGFRa.
The canine orthologous region (CFA 13q21.1-q22) resulted
significantly imbalanced in cDLBCL, although a gain, instead of
loss, was observed in 58% of dogs.
An accurate analysis comparing imbalances at the IG loci
between canine and human DLBCL revealed a frequent deletion
encompassing the canine IGL locus (CFA 26q22) (91% cases), that
has not been described in hDLBCL so far. On the other hand, the
high resolution provided by the Agilent CGH platform allowed to
identify two additional losses in the canine IGH locus (CFA 8q33)
and IGK (CFA 17q16), in 91% and 100%, respectively. The latter
corresponds to the loss in human chr2 (HSA 2p11) with a high
frequency of IGK deletions, as reported in both ABC and GCB-
hDLBCLs.
Pathway Analysis
The DAVID analysis of recurrent CNAs in cDLBCLs was
performed first by considering regions of gain and loss separately,
and then by considering all aberrant intervals together. Functional
annotations of gained regions identified a total of 52 enriched BP
terms, the majority of which (16 out of 52) were related to
Nucleotide biosynthesis (e.g. GO:0009167,purine ribonucleoside
monophosphate metabolic process, GO:0009123,nucleoside
monophosphate metabolic process). The three most enriched
terms (.10-fold enriched) were all related to Inosine Monophos-
phate (IMP) metabolic process. The most significantly enriched
KEGG pathway term was Ascorbate and Aldarate metabolism
(hsa00053, p,0.001 Fold-enrichment .10). When considering
only intervals of losses, 8 BP terms were found significantly
enriched. The most significant one was Immune response
(GO:0006955, p,0.01), which was represented mainly by IG
locus. The remaining 7 BP terms were all related to protein
synthesis (i.e. GO:0000028,ribosomal small subunit assembly)
and transcription initiation (GO:0006367,transcription initiation
from RNA polymerase II promoter, GO:0006357,regulation of
transcription from RNA polymerase II promoter). The only
KEGG pathway significantly enriched in loss regions was
Huntington’s disease (hsa05016). Functional annotation of all
CNAs without distinguishing between gains and losses identified
55 enriched BP terms, mostly overlapping (42 out of 55) with those
Figure 1. Genomic aberrations in cDLBCL. Frequency plot of CNAs in 12 pre-treatment DLBCLs. Copy number gains/amplifications and losses
are indicated as red and blue, respectively. The thresholds of log2 ratio values for single-copy number gains and losses were .0.25 and ,20.25,
respectively; the thresholds for high-level gain or amplification were defined as a log 2 ratio .1 and 1.5 respectively.
doi:10.1371/journal.pone.0111817.g001
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found to be enriched in gain intervals. Similar results were
obtained when looking for enriched KEGG pathways, where, in
addition to Ascorbate and aldarate metabolism and Huntington’s
disease pathways, steroid hormone metabolism pathways (i.e.
hsa00150: Androgen and oestrogen metabolism and hsa00140:
Steroid hormone biosynthesis, p,0.001) were the most significant.
Discussion
Genetic instability, clonal selection and evolution are important
driving forces of cancer progression, and the resulting genetic
heterogeneity is a hallmark of different clinical behavior. Oligo
aCGH has been applied to several human tumors, revealing a high
degree of heterogeneity within similar histotypes, and recurrent
regions of copy-number abnormalities in the tumoral genomic
DNA led to the discovery of genes that drive disease pathogenesis
[7–9,11].
When specifically considering hDLBCL, aCGH identified
chromosomal aberrations that were significantly more frequent
in a particular DLBCL subtype than in the others, thereby helping
re-classifying DLBCLs and identifying distinct disease entities that
are associated with clinical outcome [5].
Canine DLBCL is highly chemo-sensitive, and dose-intense
multidrug chemotherapy may lead to prolonged survival [20];
however, some DLBCLs do not respond to therapy. Identifying
CNAs associated with response to chemotherapy or survival could
be beneficial to dogs with a poor prognosis, for which new
treatments may be sought. In the present study, oligo aCGH was
applied in dogs with DLBCL, by pairing tumoral DNA with
normal DNA obtained through skin biopsies. DNA obtained from
control tissues within the same subject allowed to find somato-
genetic aberrations related to DLBCL, thereby excluding possible
polymorphic genomic variations correlated with breed. Overall,
aCGH provided a comprehensive high-resolution scanning of the
DLBCL genome and identified multiple regions of recurrent copy
number changes, one of which was significantly correlated with a
shorter duration of remission.
The analysis of the genes located within the chromosomal
segments with recurrent alterations in at least two dogs identified a
Figure 2. Example of a single genomic aberration (CFA 26q22) at different time points in dog 2. The log2 ratio value is plotted on the y-
axis; the x-axis represents the genomic position of probes on the array. The genomic profiles indicate a focal loss in chr26, involving IGL, in pre-
treatment DLBCL (upper plot) and during relapse (lower plot); the loss was not detected in clinical remission at the end of therapy (middle of plot).
doi:10.1371/journal.pone.0111817.g002
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total of 1,363 genes in pre-treatment DLBCLs. A number of
known and previously unknown oncogenes were identified, some
of which have already been reported to be associated with cancer,
including: ADCY8, ZFAT, BAI1, PTK2, FBXL6, FOXH1,
HSF1, and UGT2A1. The DAVID analysis, considering genes
belonging to gain regions, highlighted numerous molecular
pathways significantly enriched. This was mainly due to the
recurrent gain of two whole chromosomes, chr13 and chr31 that,
even if being attributable to ‘‘single events’’, contributed with an
extremely high number of genes. Interestingly, the great majority
of enriched BP terms was related to nucleotide biosynthesis and
IMP metabolism, rate-limiting step for purine synthesis, and
therefore playing an important role in the regulation of cell growth
and malignancy development. This finding was confirmed also by
KEGG analysis, with the most enriched term being Ascorbate and
aldarate metabolism, pathway reported to be dis-regulated in
breast and ovarian cancer in humans and linked to nucleotide
metabolism. The only KEGG term enriched in loss regions was
Huntington’s disease, represented mainly by genes involved in
oxydative phosphorylation (OxPhos). This finding is of particular
interest if considering that OxPhos deficits have been recently
associated with malignancies and tumor growth [21,22]. When
considering only deleted regions, the most significant BP pathway
was the Immune response. This was not surprising, given the
extremely high frequency of IG heavy and light chain loci
deletions detected in cDLBCL that involve both IGK, IGL and
IGH. Even if the canine IGH locus is minimally annotated,
comparison with human orthologous genes locates the canine IGH
locus in CFA 8q33 (72.95 to 74.12 Mb), a region frequently found
to be deleted in cDLBCL (91%). The loss of IGK (CFA 17q15) in
pre-treatment DLBCLs was found in all cases (100%), and the
same region was also identified in the three relapsed DLBCLs and
in the lymph nodes of two dogs that were in remission at the end of
therapy. Similar evidence was found for the IGL locus (CFA
26q22), deleted in 91% of pre-treatment DLBCLs and in the three
relapsed dogs.
A previous study with BACs in dogs with B-cell lymphoma
reported a similar frequency for the IGL deletion, but the loss of
IGK was less common [6]. One possible explanation for this
discordance is the different technical approach. High-density oligo
arrays are able to identify microaberrations that are beyond the
limits of detection of the BAC array platform. In addition,
different B-cell lymphoma histotypes were included in the previous
study. Based on our results, clonal rearrangement of immuno-
globulin light and heavy chains is manifested as a recurrent loss of
IGK, IGL and IGH, thereby becoming a hallmark event in
DLBCL. These new findings are in concordance with those
referring to human DLBCL [23].
As previously mentioned, the loss of IGK locus is a common
event also in human B-cell lymphomas (BCL) [16], while no
chromosomal deletions have been reported for IGL (HAS 22q11)
or IGHV (HSA 14q32) genes, even if these loci are common
targets for rearrangements in hBCL. Indeed, a hallmark of hBCLs
are balanced chromosomal translocations involving the IGHV
locus. The most frequent are t(14; 18) (q32; q21) and t(8; 14) (q24;
q32), that give rise to the BCL-2/Ig and MYC/Ig fusions,
respectively [24]. These translocations, besides resulting in
dysregulated expression of oncogenes, cause disruption and non-
functionality of the involved IGH chain gene [25,26]. A recent
study [27] also demonstrated that MYC translocation with IG
partner gene has a negative prognostic impact compared with non
IG-MYC translocation. IGHV, IGK variable (IGKV) and IGL
variable (IGLV) genes inactivation through destructive mutations
is a well-known event also in post-transplant lymphoproliferative
disorders (PTLDs), in particular in those originating from
Germinal Center B cells [28]. Taken together, these evidences
clearly demonstrate that in both dogs and humans IG heavy and
light chain loci are commonly inactivated, possibly playing an
essential role in DLBCL pathogenesis.
Remarkable in this context are the preliminary results of the
GISTIC analysis, which identified additional losses of the IGHG
locus as significantly associated with chemo-resistant cDLBCLs.
Although further investigations are required, this finding suggests
that the magnitude of IG loci losses may have clinical/prognostic
relevance for cDLBCL.
In newly diagnosed DLBCLs, gains along the length of the
chr13 were often observed in different regions. Interestingly, the
segments where MYC (,25.2 Mb), LDHB (,28.3 Mb),
PDGFRa (,47.7 Mb) and KIT (,47.1 Mb) are encoded were
the most frequently involved (66–75%). Deregulation of MYC has
been described to have a central role in cellular processes such as
proliferation, differentiation, and metabolism. Aberrations involv-
ing MYC, in terms of both gains of 8q24 or translocations t(8; 14)
(q24; q32), are a common event of hBCL and are associated with a
more aggressive phenotype and poor outcome in human DLBCL,
including shorter progression-free interval and overall survival
[29]. In the present study, the gain of the whole canine chr13 was
observed more frequently in therapy-responsive DLBCLs (5/6,
Table 2. Orthologous chromosomal regions in canine and human DLBCL.
hDLBCL
CFA location CNA HSA location CNA Ref Genes
13q21.1-q22 Gain 1p36.11 Gain [19] RUNX3
13q21.1-q22 Gain 7p13 Gain [15,16] DBNL, PGAM2
13q21.1-q22 Gain 8q24 Gain [15,16] MYC, TMEM75, NDRGI, HHLA1, ASAP1, PTK2
13q12-q13 Gain 18q21.1 Gain [15–18] RPL17, SMAD4
13q12-q13 Gain 16p12 Gain [15,16] SYT17
13q21.1-q22 Gain 19q13 Gain [15–18] QPCTL, SNRPD2, FTL
13q21.1-q22 Gain 4q12 Loss [18] KIT, PDGFRa
17q15 Loss 2p11 Loss [15,16] IGK locus
8q33 Loss 1q44 Gain [15] NLRP3
doi:10.1371/journal.pone.0111817.t002
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compared to 2/6 therapy-resistant cDLBCLs); however, when
looking specifically at the region containing MYC (24.3 to
26.3 Mb), the number of therapy-resistant DLBCLs showing
imbalance doubled in size. This finding clearly supports the
involvement of MYC in the pathogenesis of canine lymphoma,
although further studies in a higher number of cases are needed to
verify its association with clinical behavior in cDLBCL. LDHB is a
critical enzymatic activator of glycolysis and the co-respective iso-
enzymes are formed by the random combination of two different
subunits encoded by two structurally distinct genes, LDHA and
LDHB. Expression of mammalian LDHA and LDHB is regulated
during development and is tissue specific; therefore, alterations in
the LDH levels serve as indicators of pathologic involvement and
cancer development [30]. The significance and the regulation of
LDHB expression in cancer development remains unclear, but
different tumor phenotypes may originate from the alteration of
LDHA and LDHB caused by mutation, chromosomal deletion/
duplication, and increase of copy number [31]. LDH levels at the
end of chemotherapy have been also considered prognostic in
canine lymphoma by predicting early recurrence [32].
PDGFRa is a type III receptor tyrosine kinase and genetic
mutations have been reported in many human cancers [33–35]. In
humans, these receptors have drawn much attention because they
can be efficiently targeted by tyrosine kinase inhibitors. In this
study, gain of PDGFRa was found in eight pre-treatment DLBCLs
(67%) 3 of which relapsed. The dogs in clinical remission at the
end of chemotherapy never showed CNAs in this region. The gain
of PDGFRa was confirmed in a previous study [36] where
PDGFRa expression was found increased in cDLBCLs compared
to healthy controls.
It is worth noticing that although PDGFRa and KIT are
expressed in a variety of human hematopoietic neoplasms, the
chromosomal region where both genes are located (HSA 4q12) is
frequently deleted in hDLBCL [18], evidence totally in contrast
with what observed herein.
In the present study, for some dogs aCGH analysis was repeated
at the end of treatment or at relapse. When we reconsidered all
CNAs based on the clinical follow-up, we found 701 genes out of
1,363 showing recurrent mutations exclusively in dogs that did not
relapse during treatment. These genes are mainly related to the
gain of canine chr13 that we found to be significantly more
frequent in therapy-responsive DLBCLs.
A total of 656 genes were shared between not relapsing and
relapsing dogs while, notably, imbalances of 6 genes (PTGES3L,
AOC3, AOC2, MPP6, BMP2 K and PAQR3) were found
exclusively in dogs that relapsed before the end of treatment.
Interestingly, PAQR3 deletion is known to enhance tumorigenesis
in mouse models, whereas the reduced expression in human
colorectal cancer is associated with the regulation of the
proliferation [37]. Its role in lymphoma is unknown, but this data
opens new perspectives in this tumor.
In relapsed DLBCLs, a reduced number of chromosomal
rearrangements was found when compared with the correspond-
ing newly-diagnosed DLBCLs. One dog had the same profile,
suggesting a linear clonal evolution; however, the other two dogs
were more complicated in terms of aberrations, and new
rearrangements were detected. Two different scenarios can
explain these results. First, chemotherapy alters the growth
conditions of the neoplastic cells, thereby having a strong impact
on the selection process of the resistant clones. If neoplastic cells
dominating at diagnosis are sensitive to therapy, minor clones with
intrinsic resistance may be secondarily generated by the tumor,
and expand more efficiently once the competing clones are
eliminated by the treatment. In the second hypothesis, these clones
were present but undetectable in the pre-treatment lymphoma and
became evident at relapse [38]. In the dog with the same pattern
of chromosomal rearrangements, chemotherapy seemed ineffec-
tive for the neoplastic clones. Future studies should be directed on
the impact of cell growth properties and the clonal selection
process in canine DLBCL before and after treatment.
Interestingly, in dogs that were in clinical and molecular
remission at the end of chemotherapy, an unexpected number of
new gains and losses were found. A possible explanation of this
finding might be related to the fact that a reduced number of
clonal cells are still present in the lymph node, but the number of
chromosomal arrangements is insufficient for lymphoma identifi-
cation both by PARR or clinically. The histology of the lymph
nodes was similar, being characterized by atrophic follicles. The
paracortex displayed a moderate proliferation of the high
endothelial venules and a high number of plasma cells were also
present. These features were attributed to the effects of chemo-
therapy. Surprisingly, 3 dogs in remission at the end of treatment
exhibited a new loss in CFA 8q11 (2.4 to 2.9), where T-cell
receptor (TCR) alpha and delta genes are located. Moreover, one
of them showed a loss in chr16, where TCR beta is located. These
results are analogous to the findings observed in human melanoma
after administration of a vaccine consisting of autologous
melanoma cells modified with dinitrophenyl [39]. In these
patients, a TCR rearrangement in lymphocytes within the lesion
was found. These three dogs received an autologous therapeutic
vaccine in addition to chemotherapy, as previously described. The
vaccine consisted of hydroxyapatite, heat shock proteins and
proteins from the cell membrane system. Likewise human
melanoma, immunotherapy might induce TCRs rearrangements
elicited by lymphoma-associated antigens, thereby explaining the
results obtained here.
In conclusion, the current results demonstrate that the
application of oligo aCGH contributed to identifying CNAs that
provided new insight for the study of cDLBCL. Preliminary
statistical analysis highlighted regions associated with a poor
outcome in a group of dogs. Thus, our analysis provides a rich
starting point for future investigations into the molecular
pathogenesis of canine DLBCL.
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